Opus Genetics, Inc. 8-K

What Happened
Opus Genetics, Inc. filed an 8-K on April 7, 2026 disclosing that on April 1, 2026 the company entered into Change in Control Bonus Payment Agreements with four senior executives. The agreements cover Dr. George Magrath (CEO), Robert Gagnon (CFO), Joseph Schachle (COO) and Dr. Ashwath Jayagopal (Chief Scientific and Development Officer) and provide that the company will reimburse any excise taxes the executives incur in connection with a change in control under Section 4999 of the Internal Revenue Code. The form of the agreement is filed as Exhibit 10.1 to the 8-K.

Key Details

• Date of agreements: April 1, 2026; 8-K filed April 7, 2026.
• Executives covered (4): Dr. George Magrath (CEO); Robert Gagnon (CFO); Joseph Schachle (COO); Dr. Ashwath Jayagopal (CSO/Chief Scientific & Development Officer).
• Benefit: Company will reimburse executives for excise taxes incurred under IRC Section 4999 (relating to parachute payments) in connection with a change in control.
• Documentation: Form of Change in Control Bonus Agreement is included as Exhibit 10.1 to the 8-K.

Why It Matters
This creates a contingent compensation obligation the company may have to pay if a change-in-control transaction triggers excise taxes for these executives. For investors, it’s a disclosure of potential post-transaction costs and a sign the company has taken steps to protect key management from tax penalties associated with change-of-control payouts. The filing does not disclose any specific dollar amounts or thresholds—only the existence and terms (as filed) of the reimbursement agreements.